Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Does restricting Vicodin make sense?

Albert Fuchs, MD
Meds
November 1, 2013
Share
Tweet
Share

To understand the Vicodin story we first have to understand how habit-forming medicines are currently prescribed in the U.S. The Drug Enforcement Agency divides potentially addictive substances into different schedules. Schedule II controlled substances are prescription medicines that have a high potential for abuse and severe dependence. They include all the opiate (narcotic) pain medicines, like morphine, oxycodone, and fentanyl. These medications must be prescribed on a paper prescription that has special security markings that prevent copying. The prescription must be taken to the pharmacy by the patient, and cannot be faxed or phoned in. And the prescription can at most prescribe a 90 day supply of the medication without refills.

Schedule III controlled substances are prescription medicines that have less potential for abuse and dependence than the medicines in Schedule II. It includes many medications that include an opiate medicine with a non-opiate in the same tablet. Examples include hydrocodone with acetaminophen (marketed as Vicodin, Lortab, or Norco), Tylenol with codeine, and hydrocodone with ibuprofen (Vicoprofen). Prescriptions for these medicines can be called in or faxed by physicians to pharmacies, can be written for more than a 90 day supply at a time, and can include refills.

In the last decade the number of prescriptions for Schedule III pain relievers has skyrocketed, as has the number of people taking hydrocodone for non-medical reasons. Prescription drugs are now a leading cause of addiction.

After years of consideration and debate, the Food and Drug Administration released a statement recommending that all pain medications containing hydrocodone be reclassified as Schedule II. The new policy is likely to take effect next year. This would include medications such as Vicodin, Lortab, Norco, and Vicoprofen, as well as their generic equivalents.

Proponents of the plan hope this will stem the tide of prescription medicine misuse. Opponents, like the National Community Pharmacists Association and the American Cancer Society, charge that this will inconvenience legitimate patients seeking pain relief. I suspect both sides are right — both legitimate and illegitimate users of hydrocodone will be inconvenienced.

Though I’m ambivalent about the new policy, I’m reminded of a similar change a few years ago regarding pseudoephedrine (Sudafed), a nasal decongestant. Pseudoephedrine used to be over-the-counter, but because it was being used to manufacture methamphetamine — or crystal meth, a dangerous and illegal stimulant — the new law limited the amount of pseudoephedrine that can be purchased at one time and required that the patient show identification at the pharmacy to purchase it.

My objection to the pseudoephedrine rules is simply that in the several years since the new restrictions, no one has published a study (as far as I know) showing that the street price of crystal meth is higher, that the number of crystal meth addicts is lower, or any other objective measure suggesting that the new restrictions have been effective in decreasing the quantity of crystal meth available on the black market. Nevertheless, regardless of effectiveness, once a tighter regulation is in place, it is never rescinded.

I expect much the same with the new restrictions on hydrocodone — permanent inconvenience without ever measuring whether there is a benefit.

Albert Fuchs is an internal medicine physician who blogs at his self-titled site, Albert Fuchs, MD.

Prev

Thermography for breast cancer screening: Where is the evidence?

November 1, 2013 Kevin 1
…
Next

After a lifetime in medicine, where did the time go?

November 1, 2013 Kevin 2
…

Tagged as: Medications

Post navigation

< Previous Post
Thermography for breast cancer screening: Where is the evidence?
Next Post >
After a lifetime in medicine, where did the time go?

ADVERTISEMENT

More by Albert Fuchs, MD

  • Processed meats and cancer: How much is too much?

    Albert Fuchs, MD
  • This is the best way to treat chronic insomnia

    Albert Fuchs, MD
  • Paying people to quit smoking. Does it work?

    Albert Fuchs, MD

More in Meds

  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • The food-drug interaction risks your doctor may be missing

    Frank Jumbe
  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 16 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • Why health care leaders fail at execution—and how to fix it

      Dave Cummings, RN | Policy
    • How digital tools are reshaping the doctor-patient relationship

      Vineet Vishwanath | Tech
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • The hidden health risks in the One Big Beautiful Bill Act

      Trevor Lyford, MPH | Policy
  • Recent Posts

    • Why point-of-care ultrasound belongs in every emergency department triage [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why PSA levels alone shouldn’t define your prostate cancer risk

      Martina Ambardjieva, MD, PhD | Conditions
    • How to handle chronically late patients in your medical practice

      Neil Baum, MD | Physician
    • Reframing chronic pain and dignity: What a pain clinic teaches us about MAiD and chronic suffering

      Olumuyiwa Bamgbade, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
    • Why medicine must evolve to support modern physicians

      Ryan Nadelson, MD | Physician

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Does restricting Vicodin make sense?
16 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...